142 related articles for article (PubMed ID: 37690663)
1. Metabolic signature biomarkers for predicting the recurrence of urological cancers.
Amaro F; Carvalho M; Bastos ML; Guedes de Pinho P; Pinto J
Clin Chim Acta; 2023 Sep; 549():117553. PubMed ID: 37690663
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.
Speed JM; Trinh QD; Choueiri TK; Sun M
Curr Urol Rep; 2017 Feb; 18(2):15. PubMed ID: 28213859
[TBL] [Abstract][Full Text] [Related]
4. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
7. Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers.
Amaro F; Carvalho M; Bastos ML; Guedes de Pinho P; Pinto J
Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337093
[TBL] [Abstract][Full Text] [Related]
8. Uncovering the role of urinary microbiota in urological tumors: a systematic review of literature.
Karam A; Mjaess G; Albisinni S; El Daccache Y; Farah M; Daou S; Kazzi H; Hassoun R; Bou Kheir G; Aoun F; Roumeguère T
World J Urol; 2022 Apr; 40(4):951-964. PubMed ID: 34997296
[TBL] [Abstract][Full Text] [Related]
9. Current and future applications of machine and deep learning in urology: a review of the literature on urolithiasis, renal cell carcinoma, and bladder and prostate cancer.
Suarez-Ibarrola R; Hein S; Reis G; Gratzke C; Miernik A
World J Urol; 2020 Oct; 38(10):2329-2347. PubMed ID: 31691082
[TBL] [Abstract][Full Text] [Related]
10. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
11. A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma.
Lee S; Ku JY; Kang BJ; Kim KH; Ha HK; Kim S
Metabolites; 2021 Sep; 11(9):. PubMed ID: 34564407
[TBL] [Abstract][Full Text] [Related]
12. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Study of Controlling Nutritional Status (CONUT) Score as a Prognostic Factor in Patients With HIV-Related Renal Cell Carcinoma.
Xue W; Zhang Y; Wang H; Zhang Y; Hu X
Front Immunol; 2021; 12():778746. PubMed ID: 34917092
[TBL] [Abstract][Full Text] [Related]
14. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
Dai J; Tang K; Xiao W; Yu G; Zeng J; Li W; Zhang YQ; Xu H; Chen ZQ; Ye ZQ
Asian Pac J Cancer Prev; 2014; 15(8):3369-75. PubMed ID: 24870724
[TBL] [Abstract][Full Text] [Related]
16. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
Gatto F; Blum KA; Hosseini SS; Ghanaat M; Kashan M; Maccari F; Galeotti F; Hsieh JJ; Volpi N; Hakimi AA; Nielsen J
Eur Urol Oncol; 2018 Oct; 1(5):364-377. PubMed ID: 31158075
[TBL] [Abstract][Full Text] [Related]
17. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
18. Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
Alevizopoulos A; Tyritzis S; Leotsakos I; Anastasopoulou I; Pournaras C; Kotsis P; Katsarou O; Alamanis C; Stravodimos K; Constantinides C
Int J Urol; 2017 Feb; 24(2):130-136. PubMed ID: 28004432
[TBL] [Abstract][Full Text] [Related]
19. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
[TBL] [Abstract][Full Text] [Related]
20. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers.
Crispen PL; Boorjian SA; Lohse CM; Leibovich BC; Kwon ED
Cancer; 2008 Aug; 113(3):450-60. PubMed ID: 18523999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
